

Pseudohypoparathyroidism presenting with seizures: a case report and literature review

Mostafa Suhail Najim*, Riyadh Ali Mohammed Hammamy, Mohammed Awad Azzam Ashour, Asaad Omer Ahmed Imameldin

Department of Internal Medicine, Hamad Medical Corporation, Doha, Qatar.

SUMMARY Symptomatic hypocalcemia is frequently encountered in the Emergency Department, necessitating admission. It has a variety of underlying etiologies, with hypoparathyroidism and vitamin D deficiency being the most common. However, rarer etiologies such as pseudohypoparathyroidism, as was present in the current case, should not be overlooked. Reported here is a case of a young female patient presenting with generalized tonic clonic seizures. Electrocardiography revealed a prolonged QT interval which pointed towards a metabolic cause, and this was confirmed by laboratory results which indicated a low calcium level. A parathyroid pathology was obvious as the phosphate level was elevated. Pseudohypoparathyroidism, rather than hypoparathyroidism, was identified since the parathyroid hormone level was elevated. Other relevant differential diagnoses were excluded. The patient was treated with intravenous calcium initially and given regular oral calcium, calcitriol, and sevelamer.

Keywords hypocalcemia, pseudohypoparathyroidism, seizures

1. Introduction

Symptomatic hypocalcemia is frequently encountered in the Emergency Department, necessitating admission. It has a variety of underlying etiologies, with vitamin D deficiency being the most common (1). Pseudohypoparathyroidism (PHP) is an uncommon cause of hypocalcemia attributed to parathyroid hormone (PTH) resistance, with a prevalence of 3.4 per 1 million according to one Japanese study (2) and 0.79 per 100,000 according to the Orphanet Report Series, November 2008 (3). PHP is diagnosed based on the exclusion of other differential diagnoses, and it can be confirmed by genetic analysis (3).

2. Case Report

A 34-year-old woman, with a medical history of three seizures in the past for which she did not seek medical treatment, presented with generalized body weakness and a subjective fever for two days prior. While being assessed in the Emergency Department, she developed generalized tonic clonic seizures that resolved spontaneously, followed by post-ictal confusion.

On examination, vital signs were within normal limits. A systemic physical exam was unremarkable, including a neurological and a musculoskeletal

examination. Laboratory results (Table 1) revealed a very low corrected serum calcium level of 1.2 mmol/L [2.1-2.6 mmol/L] combined with a high serum phosphorus level of 1.86 mmol/L [0.87-1.45 mmol/L] in the absence of hypomagnesaemia (serum magnesium of 0.72 mmol/L [0.66-1.07 mmol/L]). These biochemical changes were combined with a high serum intact PTH of 108 pg/mL [15-65 pg/mL]. All of these findings are indicative of PHP. The low serum vitamin D level of 15 ng/mL [30-80 ng/mL] potentially added to the already low serum calcium level. Other pertinent laboratory abnormalities that suggested recent seizure activity were a high white blood cell count of $16.4 \times 10^3/\mu\text{L}$ [$4-10 \times 10^3/\mu\text{L}$] and elevated serum creatine kinase of 426 U/L [26-192 U/L].

Chest x-ray (CXR) revealed clear costophrenic angles and lung zones. The mediastinum and hila appeared normal. Cardiac size was within normal limits. Electrocardiography (ECG) (Figure 1) revealed a sinus rhythm with a prolonged QT interval (a corrected QT interval of 552), suggestive of hypocalcemia. A plain CT scan of the head (Figure 2) was unusual in that it revealed extensive bilateral symmetrical calcifications of basal ganglia, cerebellar dentate nuclei, and subcortical white matter. These calcium deposits substantiate the biochemical changes caused by PHP as mentioned above. Magnetic resonance imaging

Table 1. Laboratory results*

Laboratory results	Patient values	Normal reference range
General hematology		
White blood cell count ($10^3/\mu\text{L}$)	16.4	4 - 10
Hemoglobin (g/dL)	11.6	12 - 15
MCV (fL)	75.8	83 - 101
Platelet count ($10^3/\mu\text{L}$)	273	150 - 400
General chemistry		
Urea (mmol/L)	3.5	2.76 - 8.07
Creatinine ($\mu\text{mol/L}$)	48	53 - 97
Sodium (mmol/L)	137	135 - 145
Potassium (mmol/L)	3.1	3.6 - 5.1
Chloride (mmol/L)	92	96 - 110
Magnesium (mmol/L)	0.72	0.66 - 1.07
Glucose (mmol/L)	6.4	3.3 - 5.5
C-reactive protein (mg/L)	< 5	0 - 5
Bicarbonate (mmol/L)	17.5	24 - 30
Albumin (g/L)	47	35 - 50
Corrected calcium (mmol/L)	1.2 Low	2.1 - 2.6
Phosphorus (mmol/L)	1.86 High	0.87 - 1.45
Alkaline phosphatase (U/L)	76	45 - 129
Creatine kinase (U/L)	426	26 - 192
Myoglobin (ng/mL)	48	25 - 58
Urine chemistry		
24-hour calcium (mmol/24 hours)	2.2	2.5 - 7.5
Endocrinology		
Parathyroid hormone (pg/mL)	108 High	15 - 65
Vitamin D (ng/mL)	15 Low	30 - 80
Thyroid stimulating hormone (mIU/L)	2.51	0.27 - 4.20
Thyroxine (pmol/L)	12.1	12 - 22

*Urine cAMP was not done after PTH administration, as it was not available.




Figure 1. ECG. This ECG strip is showing sinus rhythm with prolonged QT interval (QTc 552).

(MRI) of the head (Figure 3) confirmed the findings from the head CT scan as imaging revealed bilaterally symmetric calcifications involving the dentate nuclei, basal ganglia, and subcortical white matter regions with no abnormal soft tissue component, perifocal oedema, or mass effect. Electroencephalography (EEG) revealed

bilateral frontal cerebral dysfunction but was otherwise unremarkable.

Course of treatment and outpatient follow-up: The patient was given regular intravenous calcium gluconate, regular oral calcium carbonate, calcitriol, and sevelamer. She did not experience any further




Figure 2. Plain CT head. These CT sections are showing extensive bilateral symmetrical calcifications of basal ganglia, cerebellar dentate nuclei and subcortical white matter.




Figure 3. MRI head. These MRI sections are showing bilaterally symmetric calcifications involving dentate nuclei, basal ganglia, and subcortical white matter regions with no abnormal soft tissue component, perifocal oedema, or mass effect.

seizures during hospitalization. In a post-discharge visit 1 week later, the patient was asymptomatic, corrected calcium was 1.89 mmol/L, and PTH was still high at 106 pg/mL.

3. Discussion

PTH plays a major role in keeping the body's calcium levels in check. When the serum calcium level is low, the parathyroid glands send signals to bone and the kidneys to raise serum calcium levels and maintain calcium homeostasis. These processes involve bone resorption, calcium absorption in the distal tubules, and vitamin D production *via* 1 alpha hydroxylase enzyme activation in the kidneys. Active vitamin D (1,25 dihydroxy vitamin D) will enhance intestinal absorption of calcium. When calcium levels are above normal, in contrast, the parathyroid glands are suppressed (4).

PHP, in simple terms, is hypoparathyroidism despite elevated PTH levels. This is due to the fact that the peripheral organs are unresponsive to the action of PTH. PHP is subdivided into different subtypes with different genetic mutations that include deletions, small

mutations, or methylation (loss of function) near the *GNAS* locus on chromosome 20q 13.3 (Table 2) (5,6). The latter normally mediates the action of G protein-coupled receptors *via* the transcription of a signaling protein called Gs alpha (7). PHP 1b involves a normal phenotype, which differentiates it from the other PHP 1 subtypes (PHP 1a and 1c) that have clinical features of Albright hereditary osteodystrophy (AHO); however, laboratory results, namely hypocalcemia, hyperphosphatemia, high serum PHP, and low urine cyclic adenosine 3', 5'-monophosphate (cAMP) post PTH administration, are the same (Table 2). A high PTH level is usually apparent in childhood at the age of 2-3, and hypocalcemia is mostly symptomatic in adolescence before the age of 20 (7,8). Incidental PHP has also been reported in the literature based on the presence of asymptomatic hypocalcemia as part of a preoperative work-up (9). Later, genetic testing confirmed the diagnosis of PHP 1b. The inheritance of PHP 1b follows an autosomal dominant pattern, but sporadic cases of PHP 1b reported in the literature indicate that other exogenous and environmental factors may be in play (10-12). Based on the previous

Table 2. Characteristics of PHP subtypes (5,6)

Items	PHP 1a	PHP 1b	PHP 1c	PHP II	PPHP
Phenotype	AHO + Hormonal resistance (PTH, TSH, Gn, GHRH)	Hormonal resistance (PTH +/-TSH)	AHO + Hormonal resistance (PTH, TSH, Gn)	No hormonal resistance	No hormonal resistance
Main molecular determinants	Maternal LoF in GNAS	Deletions in GNAS	No mutations	Few mutations reported	Paternal LoF in GNAS
Serum Ca	Low	Low	Low	Low	Normal
Serum P	High	High	High	High	Normal
Serum PTH	High	High	High	High	Normal
Urine cAMP post PTH	Low	Low	Low	Normal	Normal

AHO, Albright hereditary osteodystrophy; Ca, calcium; cAMP, cyclic adenosine 3', 5'-monophosphate; GHRH, growth hormone-releasing hormone; Gn, gonadotropin; LoF, loss of function; P, phosphorus; PHP, pseudohypoparathyroidism; PPHP, pseudo-pseudohypoparathyroidism; PTH, parathyroid hormone; TSH, thyroid stimulating hormone.

Table 3. Studies reporting late PHP 1b presentation

Author, year (Ref.)	Age, gender	Patient characteristics	Clinical manifestations	Vitamin D level	Brain imaging
Iglesias <i>et al.</i> , 2017 (8)	65 year-old, female	Normal phenotype	Asymptomatic	Normal	Not done
Chong <i>et al.</i> , 2013 (13)	46 year-old, female	Normal phenotype	Symptomatic	Low	Not done
Chale-Matsau <i>et al.</i> , 2018 (14)	33 year-old, female	Normal phenotype	Symptomatic	Normal	Not done
Aggarwal <i>et al.</i> , 2016 (15)	23 year-old, female	Normal phenotype	Symptomatic	Normal	Normal
Van Rooijen <i>et al.</i> , 2012 (16)	18 year-old, female	Normal phenotype	Symptomatic	Low	Not done
Zeniya <i>et al.</i> , 2014 (17)	22 year-old, female	AHO phenotype	Symptomatic	Normal	Bilateral calcifications
Garg <i>et al.</i> , 2011 (18)	34 year-old, male	Normal phenotype	Symptomatic	Normal	Normal

AHO, Albright hereditary osteodystrophy; PHP: pseudohypoparathyroidism.

discussion, the current patient was deemed to be a late presenter of sporadic PHP 1b.

While there are numerous case reports addressing PHP 1b in the pediatric population, there are few PHP 1b cases involving a late presentation. Moreover, most of the published articles focus on the genetic mutations of the disease rather than the clinical aspects and disease implications. A review of the literature identified 7 relevant case reports that share some similarities as well as differences with the current case (Table 3) (8,13-18).

Hypoparathyroidism and PHP are the most common causes of basal ganglia calcifications. Together, they account for more than two-thirds of cases (19). There is some evidence that extracellular phosphate accumulation may play a major role in the formation of these calcifications (20). Widespread calcifications beyond the basal ganglia, as were present in the current case, are uncommon in PHP (21). Such extensive calcifications might be asymptomatic or have been likened to seizures or more severe neurological manifestations such as parkinsonism and impaired mental function (19). Other rarer causes of basal ganglia calcifications include Down's syndrome, Fahr's syndrome, tuberous sclerosis, and Cockayne syndrome (22).

PHP can cause serious skeletal complications if left untreated. This is attributable to the accompanying secondary hyperparathyroidism due to the resistance of renal receptors to the action of PTH. If this persists

long enough, it can reduce bone density, and mainly that of cancellous bones, *via* accelerated bone turnover (23). Elevated serum alkaline phosphatase (ALP) can be a marker of PHP-related bone disease that warrants a thorough skeletal survey (24).

The current patient presented with seizures, and this can be explained by the effects of PHP; namely hypocalcemia and widespread cortical and basal ganglia calcifications as were mentioned earlier. In addition, vitamin D deficiency reduced the patient's calcium level even lower and might have contributed to clinically evident seizures. Normal serum ALP precluded the need for a detailed skeletal survey (Table 1). In conclusion, PHP is a rare cause of hypocalcemia that should be considered among differential diagnoses. The two aspects that distinguish the current case are the late presentation of the disease and the potentially preventable bone disease that may occur if the diagnosis of PHP is missed.

References

- Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. *BMJ*. 2008; 336:1298-1302.
- Nakamura Y, Matsumoto T, Tamakoshi A, Kawamura T, Seino Y, Kasuga M, Yanagawa H, Ohno Y. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. *J Epidemiol*. 2000; 10:29-33.
- Mantovani G. Clinical review: Pseudohypoparathyroidism: diagnosis and treatment. *J Clin Endocrinol Metab*. 2011;

- 96:3020-3030.
4. Poole K, Reeve J. Parathyroid hormone — A bone anabolic and catabolic agent. *Curr Opin Pharmacol.* 2005; 5:612-617.
 5. Navaeifar MR, Zamanfar D. Calcification of soft tissues in a family, case report and review of pseudohypoparathyroidism. *Journal of Rare Disorders: Diagnosis & Therapy.* 2017; 3:16.
 6. Mantovani G, Spada A, Elli FM. Pseudohypoparathyroidism and Gs α -cAMP-linked disorders: current view and open issues. *Nat Rev Endocrinol.* 2016; 12:347-356.
 7. Jüppner H. Genetic and epigenetic defects at the GNAS locus cause different forms of pseudohypoparathyroidism. *Ann Endocrinol (Paris).* 2015; 76:92-97.
 8. Iglesias Bolaños P, Gutierrez Medina S, Bartolomé Hernandez L. Late diagnosis of 1b pseudohypoparathyroidism. *Med Clin (Barc).* 2017; 149:508-509.
 9. Goto M, Yamamoto Y, Ishii M, Nakamura A, Sano S, Kagami M, Fukami M, Saito R, Araki S, Kubo K, Kawagoe R, Kawada Y, Kusuhara K. Sporadic pseudohypoparathyroidism type-1b with asymptomatic hypocalcemia. *Pediatr Int.* 2016; 58:1229-1231.
 10. Bastepe M, Fröhlich LF, Hendy GN, Indridason OS, Josse RG, Koshiyama H, Körkkö J, Nakamoto JM, Rosenbloom AL, Slyper AH, Sugimoto T, Tsatsoulis A, Crawford JD, Jüppner H. Autosomal dominant pseudohypoparathyroidism type 1b is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. *J Clin Invest.* 2003; 112:1255-1263.
 11. Morgado J, Dias P, Sampaio M, Sousa A. A sporadic case of pseudohypoparathyroidism type 1b. *Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo.* 2016; 11:212-214.
 12. Donghi V, Mora S, Zamproni I, Chiumello G, Weber G. Pseudohypoparathyroidism, an often delayed diagnosis: a case series. *Cases J.* 2009; 2:6734.
 13. Chong P, Meeking D. Pseudohypoparathyroidism: a rare but important cause of hypocalcaemia. *BMJ Case Rep.* 2013; 2013:bcr2012008040.
 14. Chale-Matsau B, van Niekerk C, Kemp T, Pillay T. Discordant calcium and parathyroid hormone with presumed epileptic seizures. *Clin Chem.* 2018; 64:442-445.
 15. Aggarwal A, Shah R, Mousa O, Patel A. Isolated PTH renal resistance pseudohypoparathyroidism 1b: a rare cause of hypocalcemia. *JNMA J Nepal Med Assoc.* 2016; 55:33-35.
 16. Van Rooijen C, Kok M, Simsek S, Stam F. Ain't no sunshine when she's gone: pseudohypoparathyroidism discovered in an adult. *Case Rep Endocrinol.* 2012; 2012: 739375.
 17. Zeniya S, Yuno A, Watanabe T, Usui T, Moriki Y, Uno Y, Miake H. A 22-year-old woman with hypocalcemia and clinical features of Albright hereditary osteodystrophy diagnosed with sporadic pseudohypoparathyroidism type 1b using a methylation-specific multiplex ligation-dependent probe amplification assay. *Intern Med.* 2014; 53:979-986.
 18. Kharb S, Gundgurthi A, Dutta M, Garg M. Adult onset pseudohypoparathyroidism type-1b with normal phosphaturic response to exogenous parathyroid hormone. *Indian J Endocrinol Metab.* 2011; 15:337-340.
 19. Koller WC, Cochran JW, Klawans HL. Calcification of the basal ganglia: computerized tomography and clinical correlation. *Neurology.* 1979; 29:328-333.
 20. Mitchell D, Regan S, Cooley M, Lauter K, Vrla M, Becker C, Burnett-Bowie S, Mannstadt M. Long-term follow-up of patients with hypoparathyroidism. *J Clin Endocrinol Metab.* 2012; 97:4507-4514.
 21. Montenegro A, Gelenske T, Carvalho É, Bandeira F, Sougey E. First description of pseudohypoparathyroidism with frontal lobe calcification and normal serum calcium at the initial manifestation in an otherwise healthy seven-year-old girl. *Arq Bras Endocrinol Metabol.* 2011; 55:349-352.
 22. Basak R. A case report of basal ganglia calcification - a rare finding of hypoparathyroidism. *Oman Med J.* 2009; 24:220-222.
 23. Tollin S, Perlmutter S, Aloia J. Serial changes in bone mineral density and bone turnover after correction of secondary hyperparathyroidism in a patient with pseudohypoparathyroidism type 1b. *J Bone Miner Res.* 2000;15:1412-1416.
 24. Kidd G, Schaaf M, Adler R, Lassman M, Wray H. Skeletal responsiveness in pseudohypoparathyroidism. *Am J Med.* 1980; 68:772-781.

Received April 8, 2020; Revised May 10, 2020; Accepted May 24, 2020.

*Address correspondence to:

Mostafa Suhail Najim, Department of Internal Medicine, Hamad Medical Corporation, Al Rayyan Street, Hamad General Hospital, P.O. Box 3050, Doha, Qatar.
E-mail: drmostafanajim@gmail.com

Released online in J-STAGE as advance publication June 2, 2020.